|
AAs | Dose | Administration method | Models | Major functions and effects | Ref. |
|
Tryptophan | 88 mg/kg⋅BW⋅day | Intragastric infusion | Piglets | Amelioration of clinical symptoms; reduction of gut permeability and cell apoptosis; inhibition of the production of inflammatory cytokines (TNF-α, IL-6, IFN-γ, IL-12p40, IL-1β, and ICAM-1) | [35] |
|
Melatonin | 20 mg/kg⋅BW⋅day | Intragastric infusion | Rats | Antioxidant; inhibition of the production of inflammatory cytokines (TNF-α, COX-2, SOD, and NF-κB); accelerating healing of gastric ulcer | [36] |
|
Glutamine | 25% of the total nitrogen | Dietary | Mice | Anti-inflammation; reduction of expression of PSGL-1, LFA-1, and CCR9 by Th cells | [37] |
|
Glutamate | 12 μg Glu/0.3 μL saline | Microinjection | Rats | Neurotransmitter; inhibition of T-cell response and inflammation | [38] |
|
Methionine | 0.12% L-Met | Dietary | Piglets | Protection of the small-intestinal mucosa | [39] |
|
Cysteine | 144 mg/kg⋅BW⋅day | Intragastric infusion | Piglets | Reduction of intestinal permeability and cell apoptosis; inhibition of the local expression of inflammatory mediators (IL-6, TNF-α, IL-12p40, and IL-1β) | [40] |
|
Histidine | Not mentioned | Dietary | Mice | Reduction of histologic damage, colon weight, IL-6, and TNF-α production; inhibition of NF-κB | [41] |
|
Arginine | 1% (wt/vol) solution | Drinking water | Mice | Improvement of the clinical parameters and body weight loss; reduction of the colonic permeability; reduction of the proinflammatory cytokine and chemokine expression | [42] |
|
Glycine | 5% Gly | Dietary | Rats | Diarrhea amelioration; prevention of the increases of IL-1β and TNF-α | [43] |
|
Taurine | 30 mM | Rectal administration | Rats | Anti-inflammation; inhibiting NF-κB activity | [44] |
2% | Drinking water | Mice | Inhibitory effects on the secretion of MIP-2; cytoprotective functions on the epithelial barrier | [45] |
|